SNPHY (Santen Pharmaceutical Co) Research & Development: $172 Mil (TTM As of Mar. 2026)


SNPHY Santen Pharmaceutical Co Ltd SNPHY
87 GF Score
Price $12.36
GF Value $10.15
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Research & Development?

Santen Pharmaceutical Co SNPHY 87 Research & Development is $172 Mil as of Mar. 2026. GuruFocus rates SNPHY with a GF Score™ of 87/100 and a GF Value™ of $10.15 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Santen Pharmaceutical Co's Research & Development for the three months ended in Mar. 2026 was $49 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $172 Mil.

Santen Pharmaceutical Co  (OTCPK:SNPHY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Santen Pharmaceutical Co Research & Development Related Terms

Santen Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Research & Development Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 222.45 211.70 169.65 161.70 165.02

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.18 42.96 41.69 38.49 49.24
SNPHY
87GF Score
Santen Pharmaceutical Co Ltd SNPHY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $172 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $172 Mil mean?
Santen Pharmaceutical Co (SNPHY) has a Research & Development of $172 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Research & Development too high?
Santen Pharmaceutical Co's current Research & Development is $172 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Research & Development compare to LLY and JNJ?
Santen Pharmaceutical Co's Research & Development of $172 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Research & Development is $172 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHY) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.15, compared to a current price of $12.36 — trading 21.8% above its estimated fair value. The current Research & Development is $172 Mil. Santen Pharmaceutical Co's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHY), the current Research & Development is $172 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHY) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $12.36 is trading 21.8% above its estimated GF Value™ of $10.15. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHY:

  • Research & Development: $172 Mil
  • GF Value™: $10.15 vs. price of $12.36 (21.8% above fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the SNPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges 4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
87GF Score

Get the complete analysis for SNPHY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.36
Price
$10.15
GF Value